RUBICON2025-10-012025-12-31RUBICON2025-12-31RUBICON2025-10-012025-12-31CompositionOfBoardOfDirectors1RUBICON2025-12-31CompositionOfBoardOfDirectors1RUBICON2025-10-012025-12-31CompositionOfBoardOfDirectors2RUBICON2025-12-31CompositionOfBoardOfDirectors2RUBICON2025-10-012025-12-31CompositionOfBoardOfDirectors3RUBICON2025-12-31CompositionOfBoardOfDirectors3RUBICON2025-10-012025-12-31CompositionOfBoardOfDirectors4RUBICON2025-12-31CompositionOfBoardOfDirectors4RUBICON2025-10-012025-12-31CompositionOfBoardOfDirectors5RUBICON2025-12-31CompositionOfBoardOfDirectors5RUBICON2025-10-012025-12-31CompositionOfBoardOfDirectors6RUBICON2025-12-31CompositionOfBoardOfDirectors6RUBICON2025-10-012025-12-31CompositionOfBoardOfDirectors7RUBICON2025-12-31CompositionOfBoardOfDirectors7RUBICON2025-10-012025-12-31CompositionOfBoardOfDirectors8RUBICON2025-12-31CompositionOfBoardOfDirectors8RUBICON2025-10-012025-12-31CompositionOfCommittees14RUBICON2025-12-31CompositionOfCommittees14RUBICON2025-10-012025-12-31CompositionOfCommittees15RUBICON2025-12-31CompositionOfCommittees15RUBICON2025-10-012025-12-31CompositionOfCommittees16RUBICON2025-12-31CompositionOfCommittees16RUBICON2025-10-012025-12-31CompositionOfCommittees41RUBICON2025-12-31CompositionOfCommittees41RUBICON2025-10-012025-12-31CompositionOfCommittees42RUBICON2025-12-31CompositionOfCommittees42RUBICON2025-10-012025-12-31CompositionOfCommittees43RUBICON2025-12-31CompositionOfCommittees43RUBICON2025-10-012025-12-31CompositionOfCommittees68RUBICON2025-12-31CompositionOfCommittees68RUBICON2025-10-012025-12-31CompositionOfCommittees69RUBICON2025-12-31CompositionOfCommittees69RUBICON2025-10-012025-12-31CompositionOfCommittees70RUBICON2025-12-31CompositionOfCommittees70RUBICON2025-10-012025-12-31CompositionOfCommittees95RUBICON2025-12-31CompositionOfCommittees95RUBICON2025-10-012025-12-31CompositionOfCommittees96RUBICON2025-12-31CompositionOfCommittees96RUBICON2025-10-012025-12-31CompositionOfCommittees97RUBICON2025-12-31CompositionOfCommittees97RUBICON2025-10-012025-12-31CompositionOfCommittees122RUBICON2025-12-31CompositionOfCommittees122RUBICON2025-10-012025-12-31CompositionOfCommittees123RUBICON2025-12-31CompositionOfCommittees123RUBICON2025-10-012025-12-31CompositionOfCommittees124RUBICON2025-12-31CompositionOfCommittees124RUBICON2025-12-31MeetingOfBoardOfDirectors1RUBICON2025-10-012025-12-31MeetingOfBoardOfDirectors1RUBICON2025-12-31MeetingOfBoardOfDirectors2RUBICON2025-10-012025-12-31MeetingOfBoardOfDirectors2RUBICON2025-12-31MeetingOfBoardOfDirectors3RUBICON2025-10-012025-12-31MeetingOfBoardOfDirectors3RUBICON2025-12-31MeetingOfBoardOfDirectors4RUBICON2025-10-012025-12-31MeetingOfBoardOfDirectors4RUBICON2025-12-31MeetingOfBoardOfDirectors5RUBICON2025-10-012025-12-31MeetingOfBoardOfDirectors5RUBICON2025-12-31MeetingOfBoardOfDirectors6RUBICON2025-10-012025-12-31MeetingOfBoardOfDirectors6RUBICON2025-12-31MeetingOfBoardOfDirectors7RUBICON2025-10-012025-12-31MeetingOfBoardOfDirectors7RUBICON2025-12-31MeetingOfBoardOfDirectors8RUBICON2025-10-012025-12-31MeetingOfBoardOfDirectors8RUBICON2025-12-31MeetingOfBoardOfDirectors9RUBICON2025-10-012025-12-31MeetingOfBoardOfDirectors9RUBICON2025-12-31MeetingOfBoardOfDirectors10RUBICON2025-10-012025-12-31MeetingOfBoardOfDirectors10RUBICON2025-10-012025-12-31MeetingOfCommittees1RUBICON2025-12-31MeetingOfCommittees1RUBICON2025-10-012025-12-31MeetingOfCommittees2RUBICON2025-12-31MeetingOfCommittees2RUBICON2025-10-012025-12-31MeetingOfCommittees3RUBICON2025-12-31MeetingOfCommittees3RUBICON2025-10-012025-12-31MeetingOfCommittees4RUBICON2025-12-31MeetingOfCommittees4RUBICON2025-10-012025-12-31MeetingOfCommittees5RUBICON2025-12-31MeetingOfCommittees5RUBICON2025-10-012025-12-31MeetingOfCommittees6RUBICON2025-12-31MeetingOfCommittees6RUBICON2025-10-012025-12-31MeetingOfCommittees7RUBICON2025-12-31MeetingOfCommittees7RUBICON2025-10-012025-12-31MeetingOfCommittees8RUBICON2025-12-31MeetingOfCommittees8RUBICON2025-10-012025-12-31MeetingOfCommittees9RUBICON2025-12-31MeetingOfCommittees9RUBICON2025-10-012025-12-31MeetingOfCommittees10RUBICON2025-12-31MeetingOfCommittees10RUBICON2025-10-012025-12-31MeetingOfCommittees11RUBICON2025-12-31MeetingOfCommittees11RUBICON2025-10-012025-12-31MeetingOfCommittees12RUBICON2025-12-31MeetingOfCommittees12RUBICON2025-10-012025-12-31MeetingOfCommittees13RUBICON2025-12-31MeetingOfCommittees13RUBICON2025-09-30RUBICON2025-12-31OngoingTaxLitigationsOrDisputesDomain1RUBICON2025-12-31OngoingTaxLitigationsOrDisputesDomain2RUBICON2025-12-31OngoingTaxLitigationsOrDisputesDomain3RUBICON2025-12-31OngoingTaxLitigationsOrDisputesDomain4RUBICON2025-12-31OngoingTaxLitigationsOrDisputesDomain5RUBICON2025-12-31OngoingTaxLitigationsOrDisputesDomain6RUBICON2025-12-31OngoingTaxLitigationsOrDisputesDomain7xbrli:pure544578RUBICONNOTLISTEDINE506V01022RUBICON RESEARCH LIMITED2025-04-012026-03-31Quarterly2025-12-31EquitytruetruefalseDuring the quarter ended December 31, 2025, there no such Acquisition of Shares or voting Rights in Unlisted Companies by the Company required to be disclosed in this report.falseDuring the quarter ended December 31, 2025, there is no imposition of fine or penalty levied on the company.truetrueAny othertruecomr07665OriginaltruefalseMrsPratibha Sudhir Pilgoankar******00401516Executive DirectorNot ApplicableMD1954-06-12falseActiveNA2000-06-011000MrParag Sugnachand Sancheti******07686819Executive DirectorNot ApplicableCEO1983-10-16falseActiveNA2017-01-271010MrVarun Talukdar******08312687Non-Executive - Non Independent DirectorNot Applicable1984-05-18falseActiveNo2023-09-051000MrShantanu Rastogi******06732021Non-Executive - Non Independent DirectorNot Applicable1979-03-26falseActiveNo2019-04-033020MrAnand Agarwal******06481297Non-Executive - Non Independent DirectorNot Applicable1976-05-12falseActiveNo2025-01-031000MrChangavalli Venkat******02391159Non-Executive - Independent DirectorChairperson1953-09-25falseActiveNo2024-06-112024-06-1118.21110MrKumarapuram Gopalakrishnan Ananthakrishnan******00019325Non-Executive - Independent DirectorNot Applicable1957-02-10falseActiveNo2024-06-112024-06-1118.23342MrMilind Anil Patil******02546815Non-Executive - Independent DirectorNot Applicable1963-11-01falseActiveNo2024-07-112024-07-1117.212221truetruetruetruetrueAudit Committee02546815Milind Anil PatilNon-Executive - Independent DirectorChairperson2024-07-24Audit Committee02391159Changavalli VenkatNon-Executive - Independent DirectorMember2024-07-24Audit Committee06732021Shantanu RastogiNon-Executive - Non Independent DirectorMember2024-07-24Nomination and remuneration committee00019325Kumarapuram Gopalakrishnan AnanthakrishnanNon-Executive - Independent DirectorChairperson2024-07-24During the quarter, Mr. Kumarapuram Gopalakrishnan Ananthakrishnan was re-designated from Member to Chairperson with effect from October 13, 2025.Nomination and remuneration committee06732021Shantanu RastogiNon-Executive - Non Independent DirectorMember2024-07-24Nomination and remuneration committee02391159Changavalli VenkatNon-Executive - Independent DirectorMember2024-07-24During the quarter, Mr. Venkat Changavalli was re-designated from Chairperson to Member with effect from October 13, 2025.Stakeholders Relationship Committee00019325Kumarapuram Gopalakrishnan AnanthakrishnanNon-Executive - Independent DirectorChairperson2024-07-24Stakeholders Relationship Committee06732021Shantanu RastogiNon-Executive - Non Independent DirectorMember2024-07-24Stakeholders Relationship Committee07686819Parag Sugnachand SanchetiExecutive DirectorMember2024-07-24Risk Management Committee07686819Parag Sugnachand SanchetiExecutive DirectorChairperson2024-07-24Risk Management Committee02546815Milind Anil PatilNon-Executive - Independent DirectorMember2024-07-24Risk Management Committee08312687Varun TalukdarNon-Executive - Non Independent DirectorMember2024-07-24Corporate Social Responsibility Committee00401516Pratibha Sudhir PilgoankarExecutive DirectorChairperson2014-12-27Corporate Social Responsibility Committee07686819Parag Sugnachand SanchetiExecutive DirectorMember2017-02-21Corporate Social Responsibility Committee02391159Changavalli VenkatNon-Executive - Independent DirectorMember2024-07-242025-07-30true8722025-08-066true8732025-08-1811true8632025-09-1123true8612025-09-197true8722025-10-0111true8732025-10-1311true8632025-10-2915true8732025-11-1314true8832025-12-1632true883Audit Committee2025-07-30true3320Audit Committee2025-08-066true3320Audit Committee2025-08-1811true3320Audit Committee2025-09-1931true3320Audit Committee2025-10-0111true3320Audit Committee2025-11-1241true3320Audit Committee2025-11-130true3320Nomination and remuneration committee2025-07-30true3210Nomination and remuneration committee2025-09-1142true3210Nomination and remuneration committee2025-09-197true3210Nomination and remuneration committee2025-10-2939true3320Corporate Social Responsibility Committee2025-07-30true3310Corporate Social Responsibility Committee2025-11-13105true3310truetruetruetrueYestruetruefalseThe Company was listed during the quarter with effect from October 16, 2025. Accordingly, the filing of the Integrated Corporate Governance Report for the previous quarter, i.e., the quarter ended September 30, 2025, was not applicable to the Company. Further, this report will be placed before the Board of Directors at its forthcoming Board Meeting.Ms. Deepashree TanksaleCompany Secretary and Compliance OfficerfalseMs. Deepashree TanksaleCompany Secretary and Compliance OfficerThane2026-01-280131300Office of the assessment unit of Income Tax Department2022-09-26Status: Company has filed an appeal dated October 21, 2022 with Hon’ble Commissioner of Income-Tax (Appeals). The matter is currently pending. Brief: Company received an assessment order dated September 26, 2022 (“AO Order”) from the office of the assessment unit of Income Tax Department under section143(3) read with section 144 B of the Income Tax Act, 1961 for an outstanding demand of ₹ 55.51 million imposed by assessing officer for the A.Y. 2020-21. The order was passed for inter alia disallowance u/s 14A and 37 of Income Tax Act, 1961 of the expense claimed on account of the difference between issue price and face value of shares issued pursuant to the ESOP Scheme of ₹ 79.41 million. Submissions were filed and the matter is awaiting for disposal. No final adverse order has been passed as on 31-12-2025.Office of the assessment unit of Income Tax Department2023-07-26Status: Company filed an appeal dated April 19, 2024 with Hon’ble Commissioner of Income-Tax (Appeals), in relation to the demand for additional income tax raised. The matter is currently pending. Brief: Company received an assessment order dated July 26, 2023 (“AO Order”) from the office of the assessment unit of Income Tax Department under section143(3) read with section 144 B of the Income Tax Act, 1961 for CASS scrutiny on the return of income filed. The total additional income tax demand raised as per AO Order is ₹ 407.36 million.Matter is awaiting adjudication; no final order received as on 31-12-2025.Intimation order u/s 143(1) of the Income Tax Act, 19612023-12-29Status: Company is awaiting a reply and the matter is currently pending. Brief: Company received an intimation order u/s 143(1) of the Income Tax Act, 1961 dated December 12, 2023 for an outstanding amount payable of ₹ 81.42 million. On December 29, 2023, our Company paid ₹ 75.24 million out of the outstanding amount payable determined by the intimation order dated December 12, 2023. Further, our Company intimated by way of a letter dated March 28, 2024 to Assessing Offer of the Income Tax Department about the foreign tax benefit claim (“Claim”) for A.Y. 2021-2022 and 2022-2023 on inter-corporate loan extended to wholly owned subsidiary in USA and had filed the belated form 67 for A.Y. 2021-2022 and 2022-2023 and claimed credit for the interest income on the said loan in income tax return filed for A.Y. 2023-24.Matter pending with the Income-tax Department as on 31-12-2025. No final rectification / disposal as on 31-12-2025.Edenbridge Pharmaceuticals LLC2025-03-13Status: Ongoing. The matter is currently pending. Brief: Edenbridge Pharmaceuticals LLC filed a complaint against the Company and Advagen Pharma Ltd (Material Subsidiary) before before the Court of Chancery for the State of Delaware, for: (i) breach of contract; (ii) misappropriation of trade secrets; and (iii) unjust enrichment. The Company and its Material Subsidiary has denied breach of the said confidentiality agreement.(Refer Prospectus for detailed proceedings)Status: Ongoing. The matter is currently pending. Brief: Plaintiff withdrew it’s Motion for Preliminary Injunction on 26-09-2025.Pfizer INC. and Pfizer Ireland Pharmaceuticals2024-05-23Status: Ongoing. The matter is currently pending. Brief:Pfizer INC. and Pfizer Ireland Pharmaceuticals filed a complaint against the Company before United States District Court for the District of Delaware, for patent infringement under patent laws of the United States of America arising from Company’s submission for abbreviated new drug application no. 219440 to the US FDA. (Refer Prospectus for detailed proceedings)Status as on December 31, 2025: Ongoing. The matter is currently pending.Pierre Fabre Medicament SAS; Université De Bordeaux; Centre Hospitalier Universitaire De Bordeaux; and Pierre Fabre Pharmaceuticals, Inc., (“Plaintiffs”)2024-07-12Status: Ongoing. The matter is currently pending. Brief:Plaintiffs filed a complaint against the Company before United States District Court for the District of Delware for patent infringement under patent laws of the United States of America arising from Plaintiff’s submission for abbreviated new drug application (ANDA) no. 219574 to the US FDA (Refer Prospectus for detailed proceedings)Status as on December 31, 2025: Ongoing. The matter is currently pending.Metacel Pharmaceuticals LLC (Counterclaim filed by Rubicon Research Limited2023-08-08The Metacel Patent Infringement Action - Metacel Pharmaceuticals LLC initiated a Complaint against Rubicon Research [Private] Limited on 29 October 2021. Rubicon won its Summary Judgment Motion, with a Final Judgment entered on 31 August 2023, the Court finding that “Rubicon’s ANDA Product that is the subject of ANDA No. 214445 (the “Rubicon ANDA”) does not infringe any claim of the ’502 patent.” Rubicon successfully defended its Judgment before the U.S. Court of Appeals for the Federal Circuit and returned the action to U.S. District Court (see e.g. Dkt. Nos. 164 and 170.) The Rubicon Antitrust Counterclaim - Defendant, Rubicon Research [Private] Limited’s First Amended Answer, Affirmative Defenses and Counterclaim was filed on 8 August 2023, thereby initiating suit against Counterclaim Defendant, Metacel. The Counterclaim action would be stayed, by virtue of Metacel’s Appeal of the Trial Court’s Final Judgment of Non-Infringement, to the U.S. Court of Appeals for the Federal Circuit. Following entry of the Fed. Cir. Opinion affirming the Trial Court’s Decision on 23 April 2025, Rubicon sought and received an Order lifting the case stay (Dkt. No. 168) and has continued to pursue its antitrust counterclaim against Metacel through 31 December 2025.Rubicon Counterclaim: Ongoing. The matter is currently in the discovery phase.